# Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

> **NCT01118728** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 223 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Sarilumab

## Key facts

- **NCT ID:** NCT01118728
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 223 (ACTUAL)
- **Why stopped:** Lack of benefit on efficacy
- **Last updated:** 2017-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01118728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01118728, "Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01118728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*